Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revvity Inc (RVTY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Revvity IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Revvity Inc vs Recursion Pharmaceuticals Inc — how do they compare? Revvity Inc trades at $115.72 (market cap $12.91B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Revvity Inc is far larger — about 7.1× Recursion Pharmaceuticals Inc's market cap, and Revvity Inc pays a 0.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

RVTYRXRX
Market Cap
$12.91B$1.81B
Sector
TechnologyHealth
52-Week High
$117.75$6.79
52-Week Low
$82.26$2.84
Enterprise Value
$15.23B$1.33B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Recursion Pharmaceuticals Inc

RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.

Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX